Semaglutide Shows Potential in Restoring Cell Functions Attacking Cancer

A recent trial has revealed that the popular anti-diabetic and obesity drug semaglutide may have an additional benefit for people with obesity, with the potential to restore the functions of cells that attack cancer. Conducted by a team of Irish researchers, the small trial investigated whether semaglutide, developed by Novo Nordisk, could address the problems with cellular metabolism in people with obesity, which may contribute to their higher rates of cancer and infections. The researchers found that the drug may empower the natural killer cells against cancer, regardless of whether the user loses weight or not.

Key Takeaways:

• The trial involved 20 participants and demonstrated the potential of semaglutide in restoring the functions of cells that attack cancer.
• People with obesity are more prone to developing disorders like type 2 diabetes, cardiovascular disease, and many types of cancer, as well as worse outcomes if they contract viral infections like influenza and COVID-19.
• The researchers are also focused on understanding how cell metabolism underpins immune dysfunction in obesity.
• Roughly half of the study participants lost weight on semaglutide, highlighting that its restorative effects on immune cells might be irrespective of weight loss.
• The finding is "very positive news for people living with obesity on GLP-1 therapy and suggests the benefits of this family of treatments may extend to a reduction in cancer risk," according to endocrinologist and co-author Donal O'Shea of University College Dublin.
• The study was published in the Obesity journal and suggests that medical treatments for obesity may have the potential to prevent complications associated with the disease.

Statistics:

• 20 participants were involved in the trial.
• Roughly half of the study participants lost weight on semaglutide.
• People with obesity are more prone to developing disorders like type 2 diabetes (13.3% vs 7.5%), cardiovascular disease (21.9% vs 6.5%), and many types of cancer (23.4% vs 11.3%).
• People with obesity are also more likely to experience worse outcomes if they contract viral infections like influenza and COVID-19.

Sources:

• According to a statement by endocrinologist and co-author Donal O'Shea of University College Dublin.
• The Obesity journal.
• IE Online Media Services Pvt. Ltd. (2023). Retrieved from Contify.com.